DB:HWT1

Stock Analysis Report

Executive Summary

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally.


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has iCAD's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HWT1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.9%

HWT1

-0.4%

DE Healthcare Services

-0.9%

DE Market


1 Year Return

149.4%

HWT1

21.3%

DE Healthcare Services

12.8%

DE Market

Return vs Industry: HWT1 exceeded the German Healthcare Services industry which returned 21.3% over the past year.

Return vs Market: HWT1 exceeded the German Market which returned 12.8% over the past year.


Shareholder returns

HWT1IndustryMarket
7 Day0.9%-0.4%-0.9%
30 Day36.6%2.1%-0.4%
90 Day75.0%6.6%2.3%
1 Year149.4%149.4%22.4%21.3%16.3%12.8%
3 Year215.5%215.5%70.2%65.8%15.8%5.7%
5 Year29.6%29.6%141.1%130.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is iCAD's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is iCAD undervalued compared to its fair value and its price relative to the market?

27.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HWT1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HWT1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HWT1 is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: HWT1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HWT1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HWT1 is overvalued based on its PB Ratio (27.4x) compared to the DE Healthcare Services industry average (3.3x).


Next Steps

Future Growth

How is iCAD forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

55.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HWT1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HWT1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HWT1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HWT1's revenue (26.3% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: HWT1's revenue (26.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HWT1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has iCAD performed over the past 5 years?

5.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HWT1 is currently unprofitable.

Growing Profit Margin: HWT1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HWT1 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.6% per year.

Accelerating Growth: Unable to compare HWT1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HWT1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (5.9%).


Return on Equity

High ROE: HWT1 has a negative Return on Equity (-165.37%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is iCAD's financial position?


Financial Position Analysis

Short Term Liabilities: HWT1's short term assets ($29.2M) exceed its short term liabilities ($16.6M).

Long Term Liabilities: HWT1's short term assets ($29.2M) exceed its long term liabilities ($16.8M).


Debt to Equity History and Analysis

Debt Level: HWT1's debt to equity ratio (221.2%) is considered high.

Reducing Debt: HWT1's debt to equity ratio has increased from 20.5% to 221.2% over the past 5 years.


Balance Sheet

Inventory Level: HWT1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: HWT1's debt is covered by short term assets (assets are 1.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HWT1 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HWT1 has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of -24.5% each year.


Next Steps

Dividend

What is iCAD's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HWT1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HWT1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HWT1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HWT1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HWT1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Mike Klein (65yo)

1.3yrs

Tenure

US$1,633,507

Compensation

Mr. Michael S. Klein, also known as Mike, has been Executive Chairman of iCAD, Inc. since November 9, 2018. Mr. Mike is Chief Executive Officer of iCAD, Inc. since December 12, 2018. Mr. Mike was an Interi ...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD1.63M) is above average for companies of similar size in the German market ($USD616.99K).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Klein
Executive Chairman & CEO1.3yrsUS$1.63mno data
Stacey Stevens
President0.9yrsUS$432.75k0.75% $1.6m
Richard Areglado
Chief Financial Officer1.2yrsUS$284.63k0.19% $395.5k
Jonathan Go
Chief Technology Officer1.1yrsUS$501.46k0.51% $1.1m
Annette Heroux
Vice President of Administration0yrsUS$177.53kno data

1.1yrs

Average Tenure

56yo

Average Age

Experienced Management: HWT1's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael Klein
Executive Chairman & CEO1.3yrsUS$1.63mno data
Nathaniel Dalton
Director0.08yrsno data0.38% $779.3k
Susan Wood
Independent Director1.4yrsUS$12.64kno data
Andrew Sassine
Independent Director4.2yrsUS$52.73k6.55% $13.6m
Rakesh Patel
Independent Director1.4yrsUS$12.02k0.25% $525.6k

1.4yrs

Average Tenure

55yo

Average Age

Experienced Board: HWT1's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.7%.


Top Shareholders

Company Information

iCAD, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: iCAD, Inc.
  • Ticker: HWT1
  • Exchange: DB
  • Founded: 1984
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$225.510m
  • Listing Market Cap: US$207.605m
  • Shares outstanding: 19.37m
  • Website: https://www.icadmed.com

Number of Employees


Location

  • iCAD, Inc.
  • 98 Spit Brook Road
  • Suite 100
  • Nashua
  • New Hampshire
  • 3062
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ICADNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 1984
HWT1DB (Deutsche Boerse AG)YesCommon StockDEEURDec 1984

Biography

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Platform, a server residing on a customer’s network that receives patient studies from the imaging modality, performs analysis, and sends results to picture archiving and communication system and/or review workstations. In addition, the company offers magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 20:40
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.